High-risk human papillomavirus detection in oropharyngeal, nasopharyngeal, and oral cavity cancers comparison of multiple methods

JAMA Otolaryngology - Head and Neck Surgery

Volumn 139, Issue 12, 2013, Pages 1320-1327

  M Walline, Heather ^a   Komarck, Chris ^b   McHugh, Jonathan B ^b   Byrd, Serena A ^b,d   Spector, Matthew E ^b   Hauff, Samantha J ^b,e   Graham, Martin P ^b   Bellile, Emily ^c   S Moyer, Jeffrey ^b   Prince, Mark E ^b   Wolf, Gregory T ^b   Chepeha, Douglas B ^b   P Worden, Francis ^b   Stenmark, Matthew H ^a   Eisbruch, Avraham ^a   Bradford, Carol R ^b   Carey, Thomas E ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^d SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER PATIENT; CLINICAL ASSESSMENT; HEAD AND NECK TUMOR; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 66; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; INTERMETHOD COMPARISON; MOUTH CANCER; NASOPHARYNX; NASOPHARYNX CANCER; OROPHARYNX; OROPHARYNX CANCER; POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; VIRUS DETECTION; WART VIRUS;

EID: 84891946150     PISSN: 21686181     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaoto.2013.5460     Document Type: Article

References (46)

1. Chen JH, Tseng TH, Ho YC, Lin HH, LinWL,Wang CJ. Gaseous nitrogen oxides stimulate cell cycle progression by retinoblastoma phosphorylation via activation of cyclins/Cdks [published correction appears in Toxicol Sci. 2004;77(1):following table of contents]. Toxicol Sci. 2003;76(1):83-90.
2. Shiboski CH, Schmidt BL, Jordan RC. Tongue and tonsil carcinoma: increasing trends in the US population ages 20-44 years. Cancer. 2005;103(9):1843-1849.
3. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst. 2000;92(9):709-720.
4. Chaturvedi AK, Engels EA, AndersonWF, Gillison ML. Incidence trends for human papillomavirusrelated and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612-619.
5. Ernster JA, Sciotto CG, O'Brien MM, et al. Rising incidence of oropharyngeal cancer and the role of oncogenic human papilloma virus. Laryngoscope. 2007;117(12):2115-2128.
6. Maxwell JH, Kumar B, Feng FY, et al. Tobacco use in human papillomavirus-positive advanced oropharynx cancer patients related to increased risk of distant metastases and tumor recurrence. Clin Cancer Res. 2010;16(4):1226-1235.
7. Maxwell JH, Kumar B, Feng FY, et al. HPV-positive/p16-positive/EBV- negative nasopharyngeal carcinoma in white North Americans. Head Neck. 2010;32(5):562-567.
8. Lo EJ, Bell D,Woo J, et al. Human papillomavirus & WHO type I nasopharyngeal carcinoma. Laryngoscope. 2010;120(suppl 4):S185.
9. Lingfei K, Pingzhang Y, Zhengguo L, Jianhua G, Yaowu Z. A study on p16, pRb, cdk4 and cyclinD1 expression in non-small cell lung cancers. Cancer Lett. 1998;130(1-2):93-101.
10. Feng FY, Kim HM, Lyden TH, et al. Intensity-modulated chemoradiotherapy aiming to reduce dysphagia in patients with oropharyngeal cancer: clinical and functional results. J Clin Oncol. 2010;28(16):2732-2738.
11. Holzinger D, Schmitt M, Dyckhoff G, Benner A, Pawlita M, Bosch FX. Viral RNA patterns and high viral load reliably define oropharynx carcinomas with active HPV16 involvement. Cancer Res. 2012;72(19):4993-5003.
12. Schmitt M, Dalstein V,Waterboer T, Clavel C, Gissmann L, Pawlita M. Diagnosing cervical cancer and high-grade precursors by HPV16 transcription patterns. Cancer Res. 2010;70(1):249-256.
13. Liang C, Marsit CJ,McClean MD, et al. Biomarkers of HPV in head and neck squamous cell carcinoma. Cancer Res. 2012;72(19):5004-5013.
14. Muñoz N, Bosch FX, de Sanjosé S, et al International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518-527.
15. Kreimer AR, Clifford GM, Boyle P, Franceschi S. Human papillomavirus types in head and neck squamous cell carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005;14(2):467-475.
16. Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F; WHO International Agency for Research on Cancer. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6(4):204.
17. Haedicke J, Iftner T. Human papillomaviruses and cancer [published online July 8, 2013]. Radiother Oncol. doi:10.1016/j.radonc.2013.06.004.
18. Nichols AC, Dhaliwal SS, Palma DA, et al. Does HPV type affect outcome in oropharyngeal cancer? J Otolaryngol Head Neck Surg. 2013;42(1):9.
19. Simonds NI, KhouryMJ, Schully SD, et al. Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. J Natl Cancer Inst. 2013;105(13):929-936.
20. Nagai MA. Genetic alterations in head and neck squamous cell carcinomas. Braz J Med Biol Res. 1999;32(7):897-904.
21. Shintani S, MiharaM, Nakahara Y, et al. Infrequent alternations of RB pathway (Rb-p16INK4A-cyclinD1) in adenoid cystic carcinoma of salivary glands. Anticancer Res. 2000;20(3B):2169-2175.
22. Calmon MF, Colombo J, Carvalho F, et al. Methylation profile of genes CDKN2A (p14 and p16), DAPK1, CDH1, and ADAM23 in head and neck cancer. Cancer Genet Cytogenet. 2007;173(1):31-37.
23. González MV, Pello MF, López-Larrea C, Suárez C, Menéndez MJ, Coto E. Loss of heterozygosity and mutation analysis of the p16 (9p21) and p53 (17p13) genes in squamous cell carcinoma of the head and neck. Clin Cancer Res. 1995;1(9):1043-1049.
24. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/MTS1 gene is frequently associated with aberrantDNAmethylation in all common human cancers. Cancer Res. 1995;55(20):4525-4530.
25. Miracca EC, Kowalski LP, Nagai MA. High prevalence of p16 genetic alterations in head and neck tumours. Br J Cancer. 1999;81(4):677-683.
26. Okami K, Reed AL, Cairns P, et al. Cyclin D1 amplification is independent of p16 inactivation in head and neck squamous cell carcinoma. Oncogene. 1999;18(23):3541-3545.
27. . YarbroughWG. The ARF-p16 gene locus in carcinogenesis and therapy of head and neck squamous cell carcinoma. Laryngoscope. 2002;112(12):2114-2128.
28. Rischin D, Young RJ, Fisher R, et al. Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial. J Clin Oncol. 2010;28(27):4142-4148.
29. Yang H, Yang K, Khafagi A, et al. Sensitive detection of human papillomavirus in cervical, head/neck, and schistosomiasis-associated bladder malignancies. Proc Natl Acad Sci U S A. 2005;102(21):7683-7688.
30. Kumar B, Cordell KG, Lee JS, et al. Response to therapy and outcomes in oropharyngeal cancer are associated with biomarkers including human papillomavirus, epidermal growth factor receptor, gender, and smoking. Int J Radiat Oncol Biol Phys. 2007;69(2)(suppl):S109-S111.
31. Kumar B, Cordell KG, Lee JS, et al. EGFR, p16, HPV Titer, Bcl-xL and p53, sex, and smoking as indicators of response to therapy and survival in oropharyngeal cancer. J Clin Oncol. 2008;26(19):3128-3137.
32. Worden FP, Kumar B, Lee JS, et al. Chemoselection as a strategy for organ preservation in advanced oropharynx cancer: response and survival positively associatedwith HPV16 copy number. J Clin Oncol. 2008;26(19):3138-3146.
33. Coutlée F, Gravitt P, Kornegay J, et al. Use of PGMY primers in L1 consensus PCR improves detection of human papillomavirus DNA in genital samples. J Clin Microbiol. 2002;40(3):902-907.
34. Gravitt PE, Peyton CL,Alessi TQ, et al. Improved amplification of genital human papillomaviruses. J Clin Microbiol. 2000;38(1): 357-361.
35. Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol. 2006;24(17):2606-2611.
36. Fakhry C,Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100(4):261-269.
37. Gillison ML. Human papillomavirus-associated head and neck cancer is a distinct epidemiologic, clinical, and molecular entity. Semin Oncol. 2004;31(6):744-754.
38. Klussmann JP,Weissenborn SJ, Wieland U, et al. Prevalence, distribution, and viral load of human papillomavirus 16 DNA in tonsillar carcinomas. Cancer. 2001;92(11):2875-2884.
39. Singhi AD, Califano J,Westra WH. High-risk human papillomavirus in nasopharyngeal carcinoma. Head Neck. 2012;34(2):213-218.
40. Punwaney R, BrandweinMS, Zhang DY, et al. Human papillomavirusmay be common within nasopharyngeal carcinoma of Caucasian Americans: investigation of Epstein-Barr virus and human papillomavirus in eastern and western nasopharyngeal carcinoma using ligation-dependent polymerase chain reaction. Head Neck. 1999;21(1):21-29.
41. Lo EJ, Bell D,Woo JS, et al. Human papillomavirus and WHO type I nasopharyngeal carcinoma. Laryngoscope. 2010;120(10):1990-1997.
42. Rassekh CH, Rady PL, Arany I, et al. Combined Epstein-Barr virus and human papillomavirus infection in nasopharyngeal carcinoma. Laryngoscope. 1998;108(3):362-367.
43. Lee LA, Huang CG, Liao CT, et al. Human papillomavirus-16 infection in advanced oral cavity cancer patients is related to an increased risk of distant metastases and poor survival. PLoS One. 2012;7(7):e40767.
44. Duray A, Descamps G, Decaestecker C, et al. Human papillomavirus DNA strongly correlates with a poorer prognosis in oral cavity carcinoma. Laryngoscope. 2012;122(7):1558-1565.
45. Zheng ZM, Baker CC. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front Biosci. 2006;11:2286-2302.
46. Pannone G, Rodolico V, Santoro A, et al. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 immunohistochemistry, consensus PCR HPV-DNA, and in situ hybridization. Infect Agent Cancer. 2012;7:4.